Clinical Testing Validates New Prostate Cancer Biopsy and Treatment Device
Posted on: Thursday, 7 July 2005, 09:00 CDT
ST. LOUIS, July 7 /PRNewswire/ -- A recent study confirms that TargetScan(TM), a new FDA-approved targeted prostate biopsy and cancer- treatment system, delivers improved biopsies for the detection and treatment of prostate cancer.
According to the study "Evaluation of TargetScan Device in Prostate Cancer Detection" performed at Washington University in St. Louis, TargetScan's application of a stationary probe with 3-D image acquisition provided better biopsy information about the location, extent and aggressiveness of prostate cancer compared to conventional biopsy techniques. For patients, these findings mean that a TargetScan biopsy may lead to improved cancer detection and more accurate prognoses.
The clinical test showed that TargetScan detected cancer more frequently upon the first biopsy than over conventional biopsy techniques. In the study performed on 20 prostatectomy specimens removed from men with prostate cancer, researchers simulated a TargetScan biopsy procedure and compared biopsy findings to those confirmed in final laboratory pathology conducted by an independent laboratory. The TargetScan biopsies identified the extent, location and the grade of cancer more accurately.
"The results of this study are statistically significant, validating the concept that TargetScan's approach to prostate biopsies can help physicians more accurately evaluate the prostate on the first biopsy and better characterize the extent and aggressiveness of cancer if it is found," said Dr. Gerald Andriole, professor of surgery and chief of urology at Washington University School of Medicine. "TargetScan biopsies should result in improved cancer detection -- saving time, money and, potentially, lives."
Additionally, the researchers suggested that TargetScan's stabilized probe coupled with its ability to reproduce biopsies and intraprostatic needle localization could improve the success of new cancer-treatment deliveries, such as brachytherapy and cryotherapy.
About Envisioneering Medical Technology
Based in St. Louis, Mo., Envisioneering Medical Technologies is dedicated to developing, manufacturing and marketing proprietary diagnostic and treatment technology for the physician community. For more information, please visit http://www.envisioneeringmedical.com/ .
Envisioneering Medical Technology
CONTACT: Cheri Winchester for Envisioneering Medical Technology,+1-636-530-3613
Web site: http://www.envisioneeringmedical.com/
Source: PRNewswire
Related Articles
- New Finding Suggests Prostate Biopsy Is Not Always Necessary
- Appetite-stimulating Hormone Is First Potential Medical Treatment For Frailty In Older Women
- Research Foundation Salutes Stand Up to Cancer, Urges Improved Prostate Cancer Imaging
- Study Suggests Green Tea May Support the Medical Treatment of Stomach and Colon Cancer
- Swiss Researchers Report on Promising New Compounds for Cancer Detection and Treatment
- Prostate Cancer Survivor, Urologist Larry L. Bans, M.D. Announces Release of Prostate Cancer DVD - 'Your Prostate Biopsy is Positive - Here's What You Should Know.'
- Access to existing medical treatments could save more lives than spending to improve the treatments
- Lidocaine suppositories curb prostate biopsy pain
- AHRQ Launches New 'Effective Health Care Program' to Compare Medical Treatments and Help Put Proven Treatments Into Practice
- Study: Racial Gap Persists in Some Medical Treatment
 |
 |
User Comments (0)
RSS Feeds